• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

PRN Pharmacal acquires VPL; Bimeda and Ceva announce agreement on equine

December 2, 2016

Acquiring companies seek to expand veterinary reach by increasing product portfolios.

Two companies in the veterinary industry recently announced acquisitions in order to expand their reach in the veterinary product arena. PRN Pharmacal plans to acquire VPL's animal health business, and Bimeda has acquired Ceva's equine product portfolio.

Photo courtesy of PRN PharmacalPRN Pharmacal to buy VPL

Pegasus Laboratories Inc., doing business as PRN Pharmacal, announced the acquisition of Veterinary Products Laboratories' (VPL's) animal health assets. The acquisition will strengthen PRN Pharmacal's product portfolio while expanding its reach into a number of therapeutic categories not previously serviced by the company, a PRN release states.

“The addition of the VPL product lines to our pharmaceutical and nutritional portfolio is a natural fit as we continue to expand and grow,” says Donna Logan, Pegasus' general manager. “At PRN our goal is to serve veterinary niche markets and the underserved needs of the animal health community.  With this acquisition we will be able to do this better than ever.”

VPL is a division of Central Life Sciences focused on inflammation support, surgical suite supplies and environmental parasite control. PRN's purchase of its assets will include the following:

> Duralactin (milk protein)

> Zentrol (calming supplement)

> The Vet-Kem family of flea and tick control products

> Monomend, Polymend and Chromend absorbable sutures

> NY-STA and PRO-STA nonabsorbable sutures

Advertisement

> Tissumend II absorbable tissue adhesive

> Optima 365 fatty acid supplement.

It will also include a continued partnership with Becton, Dickinson & Co. (BD) to represent its surgical and medical device brands in the veterinary market.

Photo courtesy of BimedaBimeda acquires Ceva equine

Bimeda Inc., an international developer, manufacturer and marketer of veterinary pharmaceuticals and animal health products, has acquired the marketing rights to Ceva Animal Health's portfolio of equine products in the United States, according to a recent release from Bimeda.

This agreement with Ceva-a veterinary health company targeting companion animals, poultry and swine-will strategically expand Bimeda into the equine market, the release states.

Ceva's U.S. portfolio includes Tildren (tiludronate disodium), Altresyn (altrenogest), ConfidenceEQ (a pheromone analog) and PentosanEQ (pentosan polysulfate). Bimeda also acquired the marketing rights for Tildren in Canada.

“This agreement is a key milestone in Bimeda's strategic expansion into the Equine market,” says Alan Kelly, Director of Commercial Development for Bimeda North America, in the release. “With a large portfolio of complementary products, Bimeda will now be in a strong position to serve the needs of equine customers in North America.”

Related Content:

MedicalEquine MedicineBreaking NewsEquine
3 Must-reads for National Poison Prevention Week
3 Must-reads for National Poison Prevention Week
UC Davis study on eye diseases in kittens
UC Davis study on eye diseases in kittens
Dr Natalie Marks to lecture on diabetes management with Dr Adam Christman
Dr Natalie Marks to lecture on diabetes management with Dr Adam Christman

Advertisement

Latest News

Xylazine moves from the stables to the streets

DEA reports widespread threat of fentanyl mixed with xylazine

3 Must-reads for National Poison Prevention Week

UC Davis study on eye diseases in kittens

View More Latest News
Advertisement